Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12...1213141516171819202122...2425»
  • ||||||||||  dimethyl fumarate / Generic mfg., Ocrevus (ocrelizumab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Real-world data on the use of Ocrelizumab, among MS patients: B-cell suppression and clinical outcomes. () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_221;    
    While 15% of patients were treatment naïve, most patients (85%) were escalated to OCR from other disease-modifying therapies: Dimethyl Fumarate (30%), Fingolimod (16%), Alemtuzumab (15%) and Natalizumab (10%)...Data suggests that the level of B-cell suppression could be a potential marker of treatment response. This should be validated in further studies with longer follow-up.
  • ||||||||||  dimethyl fumarate / Generic mfg., Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] "Progressive Multifocal Leukoencephalopathy outcomes in Multiple Sclerosis: A Systemic review and Metanalysis " () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_218;    
    In terms of DMT at the time of PML diagnosis, the most common DMT was natalizumab (185/214; 86.4%) followed by fingolimod (20/214; 9.3%) and others including dimethyl fumarate, ocrelizumab, alemtuzumab (9/214; 4.2%)...Old age and high number of copies of CSF JCV DNA are associated with worse outcome, which is either disability or death. None of the DMT are independently associated with outcome.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Clinical characteristics and outcome of late onset Multiple Sclerosis () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_121;    
    Exposure to first line treatment was documented in 34.9% of LOMS and 59.6% had been exposed to a second line treatment (defined as fingolimod, natalizumab, rituximab or alemtuzumab). The risks to reach EDSS 4.0 (HR 1.96; 95% CI 1.72-2.24) and 6.0 (HR 2.42; 95% CI 2.13-2.75) were increased in LOMS compared to AOMS.Conclusions LOMS is characterized by a significantly higher incidence of PPMS as initial disease course and increased risk of disability progression compared to AOMS even after adjustment for age, sex and course, and even though more than half of the LOMS patients had been treated with a second line DMT.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Cladribine tablets versus other DMT in achieving disability improvement in relapsing remitting multiple sclerosis patients – network meta-analysis () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_120;    
    As there is lack of head-to-head trials directly comparing CT to other highly active DMTs, an indirect comparison via network meta-analysis (NMA) was performed with placebo as a common comparator.Objectives To compare probabilities of sustained disability improvement (SDI) on the EDSS, in patients with relapsing-remitting multiple sclerosis (RRMS), treated with cladribine tablets (CT) or fingolimod (FIN), natalizumab (NAT), alemtuzumab (ALE) and ocrelizumab (OCR).Methods In compliance with the Polish HTA guidelines, a systematic review was conducted in Pubmed, Embase and Cochrane to identify clinical trials (RCT or non-RCT) evaluating 6-month SDI...NMA results revealed that Hazard Ratios (95% CrI) for achieving 6-month SDI with CT was statistically significantly higher in comparison with all other high efficacy disease modifying treatments studied in this analysis: CT vs FIN – 5,17 (1,81; 15,01), CT vs NAT – 3,06 (1,06; 8,62), CT vs ALE – 9,45 (2,79; 31,94).Conclusions Cladribine tablets treatment was associated with higher probability of sustained recovery from disability compared to fingolimod, natalizumab and alemtuzumab in RRMS patients with highly active disease. The conclusion is based on limited quality of identified clinical data.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Alemtuzumab Real World Evidence in a Private Practice Setting () -  Aug 16, 2020 - Abstract #MSDC2020MSDC_103;    
    After treatment with alemtuzumab, there was a significant reduction in annualized relapse rate, a significant increase in the proportion of patients with stable brain MRI, improvement in disability, and reduced usage of ambulatory aid. Long term follow-up of this cohort will help assess clinical efficacy in a real-world setting.
  • ||||||||||  Clinical, Reimbursement, Journal, Medicaid:  Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018. (Pubmed Central) -  Jul 30, 2020   
    The specialty drugs considered in our analysis included dimethyl fumarate, fingolimod, teriflunomide, cladribine, siponimod, alemtuzumab, natalizumab, ocrelizumab, daclizumab, glatiramer acetate, peginterferon beta-1a, interferon beta-1a, and interferon beta-1b...The growing utilization and spending trends for specialty MS medications are significant and sizable in the US Medicaid programs. Medicaid cost-containment strategy is warranted to control the economic burden of state budgets across the country.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Blood neurofilament light levels segregate treatment effects in multiple sclerosis. (Pubmed Central) -  Jul 22, 2020   
    Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic. Choice of DMT in RRMS is significantly associated with degree of reduction in pNfL, which supports a role for pNfL as a drug response marker.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
    Journal:  MAIT cell subtypes in multiple sclerosis. (Pubmed Central) -  Jul 10, 2020   
    Treatment with alemtuzumab and dimethyl fumarate decreased MAIT cell frequencies. Altogether, we have identified specific MAIT cell subtypes related to PPMS, smoking and demyelination, and MAIT cell effects of MS therapies.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Observational data, Retrospective data, Journal:  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. (Pubmed Central) -  Jul 10, 2020   
    High-efficacy therapy commenced within 2 years of disease onset is associated with less disability after 6-10 years than when commenced later in the disease course. This finding can inform decisions regarding optimal sequence and timing of multiple sclerosis therapy.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
    Journal, Adverse events:  Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. (Pubmed Central) -  Jul 9, 2020   
    This finding can inform decisions regarding optimal sequence and timing of multiple sclerosis therapy. These real-world pharmacovigilance findings suggest that DILI might be a common feature of MS drugs and call for (1) formal population-based study to verify the risk of fampridine and (2) awareness by clinicians, who should assess the possible responsibility of MS drugs when they diagnose DILI.
  • ||||||||||  Leustatin (cladribine) / J&J, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. (Pubmed Central) -  Jul 9, 2020   
    Although, further randomized controlled trials of AHSCT for MS are needed, it has become clear that improved patient selection and lower intensity conditioning regimens have reduced AHSCT associated risks and mortality and strengthened the position of AHSCT among other DMTs. Do we have enough experience and scientific support for AHSCT in MS to move from an exclusive treatment for aggressive, treatment-resistant MS and acquire broader indications, similar to other effective DMTs?
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Alemtuzumab-Induced Diffuse Alveolar Hemorrhage in a Patient with Multiple Sclerosis (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_3983;    
    There is only one published case report that describes the condition in a patient with multiple sclerosis. Our case is unique for the severity of the reaction, as well as complete recovery following discontinuation of alemtuzumab, pulsed steroid therapy, and ventilatory support.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset. (Pubmed Central) -  Jul 3, 2020   
    Alemtuzumab-induced reconstitution GD may result from early and increased cross-reactivity between antigens common to the brainstem and thyroid, or presence of shared Human Leukocyte Antigen (HLA) alleles that determine brainstem and thyroid involvement. We suggest cautious use of alemtuzumab in younger (≤32 years) pwMS with early brainstem involvement, especially those actively planning pregnancy, where alternative therapies are readily available.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Biomarker, Clinical, Journal:  Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis. (Pubmed Central) -  Jun 29, 2020   
    We raise awareness that severe B cell-mediated disease activation could develop, even after two cycles of alemtuzumab, in some vulnerable MS patients; therefore, individualized therapeutic strategies should be considered in clinical practice. We also propose that a novel regulatory B-cell subset may be a candidate for a predictive biomarker of disease activation in MS patients treated with alemtuzumab.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Alemtuzumab Induced Graves Disease () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_2034;    
    She had no exposure to contrast dye, steroids, amiodarone, supplements or biotin use...She was started on methimazole...We also recommend checking TSI, TPO antibody for high-risk patients (positive family history, past history) and thyroid US for those who have nodules or goiters before starting IRT. For those found to have abnormal TFTs, TSI or TPO, routine follow up with an Endocrinologist should be recommended during, and even after therapy completion.
  • ||||||||||  Clinical, Journal:  Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS. (Pubmed Central) -  Jun 11, 2020   
    As lymphopenia seems to be associated with a more severe disease course, all DMTs causing lymphopenia, such as cladribine, alemtuzumab, and dimethyl fumarate, need to be reviewed more thoroughly...In summary, previous coronavirus outbreaks have not shown an increased risk for immunocompromised patients. Patients with severe neuroimmunological diseases should be kept from hasty discontinuation of immunotherapy.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Lemtrada (alemtuzumab) / Sanofi
    Biomarker, Review, Journal:  CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis. (Pubmed Central) -  May 18, 2020   
    In some cases, an increased number of CD56 NK cells is associated with an increase in their regulatory function. In the current review, we will evaluate the known effect on CD56 NK cells of DMTs for MS, and will discuss their possible role as a biomarker for treatment response in MS.